Tuyển tập các báo cáo nghiên cứu khoa học ngành y học tạp chí Medical Sciences dành cho các bạn sinh viên ngành y tham khảo đề tài: The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition. | Int. J. Med. Sci. 2008 5 113 International Journal of Medical Sciences ISSN 1449-1907 2008 5 3 113-120 Ivyspring International Publisher. All rights reserved Research Paper The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition Antonio Cassio Assis Pellizzon João Salvajoli Paulo Novaes Maria Maia Ricardo Fogaroli Doglas Gides Rodrigues Horriot Radiation Oncology Department Hospital A C Camargo Sao Paulo Brazil Correspondence to Antonio Cassio Assis Pellizzon MD Rua Prof Antonio prudente 211 Liberdade Sao Paulo SP - Brazil Cep 01509-020. Phones 55-11-21895104 05 Fax 55-11-21895101 Email cassiopellizzon@ Received Accepted Published Purpose To evaluated prognostic factors and impact of the quality of planning of high dose rate brachytherapy hDR-BT for patients With local or locally advanced prostate cancer treated with external beam radiotherapy EBRT and hDR-Bt. Methods and Materials Between 1997 and 2005 209 patients with biopsy proven prostate adenocarcinoma were treated with localized EBRT and HDR-BT at the Department of Radiation-Oncology Hospital A. C. Camargo Sao Paulo Brazil. Patient s age Gleason score GS clinical stage CS initial PSA iPSA risk group for biochemical failure GR doses of EBRT and HDR-BT use of three-dimensional planning for HDR-BT 3DHDR and the Biological Effective Dose BED were evaluated as prognostic factors for biochemical control bC . Results Median age and median follow-up time were 68 and years respectively. Median EBRT and HDR-BT doses were 45 Gy and 20 Gy. The crude bC at year was . For the Low intermediate and high risk patients the bC rates at years were and respectively. Overall survival OS and disease specific survival rates at years were and .
